Main Menu

The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.

The technology involves the development of viral hemagglutinin (HA) mutants that enhance the binding affinity to sialic acid (SA) receptors on host cell surfaces. This enhanced interaction is achieved by introducing specific mutations into the HA protein, leading to increased immunogenicity and vaccine efficacy. The mutated HA proteins are then incorporated into ferritin nanoparticles, which serve as a delivery platform to enhance protein production and stability. This technology shows promise in improving vaccine design and efficacy against viral infections.

This technology entails a novel vaccine design against malaria, employing an alphavirus Virus-Like Particle (VLP) system to present a critical epitope from the Plasmodium falciparum circumsporozoite protein (PfCSP). The vaccine targets the junctional region between the N-terminus and the central repeat domain of PfCSP, a segment previously identified as vital for generating protective immunity.

This innovative HIV immunization strategy relies on mRNA technology to prime and boost immune responses, using full-length or minimally truncated Env proteins to maintain native conformation for effective membrane expression. Co-formulating Env and Gag proteins promotes virus-like particle (VLP) production in vivo, mimicking HIV's structure for better immune recognition. The regimen involves an intensive schedule of 8+ sequential immunizations and includes boosting with diverse Envs from different HIV-1 clades to broaden the immune response.

The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities.

Novel CD8+ T cell receptors (TCRs) isolated from elite HIV controllers show unprecedented affinity for conserved HIV epitopes, offering new avenues for direct immunotherapies and T cell engineering. These TCRs exhibit potential for cytotoxicity mediation against HIV-infected cells, with prospects for use in toxin-coupled treatments or as part of engineered T cell therapies. Collaborations, such as with Altor Biosciences, are enhancing these TCRs with proprietary molecules like IL-15, to bolster therapeutic efficacy.

The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results.

The technology focuses on developing clonal lineage antibodies targeting the CD4 binding site of HIV-1, serving as templates for an effective HIV-1 vaccine. Developed through collaboration with Duke, Boston, and Stanford Universities, the patent filed by Duke University in 2012. These antibodies exhibit neutralizing activity against HIV-1, designed for therapeutic and prophylactic benefits, targeting a critical site of vulnerability on the virus to stimulate the immune system.

The development of an infectious molecular clone of simian immunodeficiency virus SIVsm, known as SIVsmE543-3, marks a significant breakthrough in SIV research. This clone, derived from a late-stage biological isolate from an immunodeficient rhesus macaque with SIV-induced encephalitis, has shown robust replication in macaque immune cells and macrophages. Notably, SIVsmE543-3 exhibits resistance to neutralization by heterologous sera, which can typically neutralize genetically diverse SIV variants in vitro.

The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.